US 12,241,839 B2
Multipartite luciferase peptides and polypeptides
Virginia Kincaid, Madison, WI (US); Lance P. Encell, Madison, WI (US); Mary Hall, Madison, WI (US); Michael Killoran, Madison, WI (US); Keith Wood, Madison, WI (US); Melanie Dart, Madison, WI (US); and Trish Hoang, Madison, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on Nov. 27, 2020, as Appl. No. 17/105,925.
Claims priority of provisional application 62/941,255, filed on Nov. 27, 2019.
Prior Publication US 2021/0262941 A1, Aug. 26, 2021
Int. Cl. G01N 21/76 (2006.01); C12N 9/02 (2006.01); G01N 33/58 (2006.01)
CPC G01N 21/763 (2013.01) [C12N 9/0069 (2013.01); G01N 33/582 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A system or kit comprising two or more peptide and/or polypeptide components collectively comprising 100% sequence identity to SEQ ID NO: 788 or SEQ ID NO: 789; wherein the two or more peptide and/or polypeptide components are capable of forming a bioluminescent complex upon interacting with each other; wherein a bioluminescent signal produced by the bioluminescent complex in the presence of a coelenterazine or a coelenterazine analog substrate is substantially increased when compared to a bioluminescent signal produced by one of the peptide and/or polypeptide components individually in the presence of the coelenterazine substrate; wherein the system or kit comprises a polypeptide that corresponds structurally to 8 or fewer β strands of a Oplophorus gracilirostris luciferase.